Radio and PodcastLive Radio & PodcastsScience & Medicine
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
Listen to FDA Drug Safety Podcast, FDA's preliminary evaluation has not found evidence that use of GLP-1 RAs causes suicidal thoughts/actions.
About This Episode
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administ...
Podcast
This episode belongs to FDA Drug Safety Podcasts.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jan 26, 2024, 3:30 long, audio available.
Related Episodes
Continue listening to more episodes from FDA Drug Safety Podcasts.
Questions About This Episode
What is Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity about?
Listen to FDA Drug Safety Podcast, FDA's preliminary evaluation has not found evidence that use of GLP-1 RAs causes suicidal thoughts/actions.
Where can I listen to Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity?
You can listen to Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity from?
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity is an episode from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.
How long is this episode?
This episode is 3:30 long.
When was this episode published?
This episode was published on Jan 26, 2024.
Can I save Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from FDA Drug Safety Podcasts?
Yes. This page shows related episodes from FDA Drug Safety Podcasts when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity?
You can listen to Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity is from FDA Drug Safety Podcasts by U.S. Food and Drug Administration, Center for Drug Evaluation and Research.
What are the episode details?
Published Jan 26, 2024 and 3:30 long